Categories AlphaGraphs, Earnings, Other Industries
HR and payroll services drive Paychex profit higher
Paychex (PAYX) reported a 17% jump in earnings for the fourth quarter, helped by an increase in revenue from HR services and payroll services, besides lower income tax. The company’s stock inched up 0.29% in the premarket as its revenue exceeded the Street’s expectations.
With revenue increasing 9% to $871.1 million, the company’s earnings grew double-digits to $228.5 million or $0.63 per share. Adjusted EPS rose 13% to $0.61.
Human Resource Services (HRS) revenue increased 17% to $401 million, primarily driven by increases in client base. The company’s largest HRS revenue stream is Paychex HR Services, which includes administrative services and professional employer services. Rising demand for these resulted in double-digit growth in client worksite employees served as of May 31, 2018, compared to last year.
Payroll service revenue rose 3% to $452.4 million, riding on growth in revenue per check, which improved as a result of price increases. As of May 31, 2018, including the Lessor acquisition, Paychex served over 650,000 payroll clients.
Looking ahead into fiscal 2019, the company expects total revenue, including interest on funds held for clients, to increase in the range of 6-7% and adjusted EPS growth of about 11%. Payroll service revenue is expected to grow in the range of 2-3%, incorporating a full year of the lessor. HRS revenue is predicted to increase in the 15-20% range.
Shares of Paychex ended Tuesday’s regular trading session down 0.98% at $69 on the Nasdaq. The stock had been trading between $54.20 and $73.10 for the past 52 weeks.
Most Popular
Agentforce in focus as Salesforce (CRM) gets ready for Q3 2025 earnings
After delivering mixed results in the first half, Salesforce, Inc. (NYSE: CRM) looks poised to report strong numbers when it publishes third-quarter results next week. The Customer relationship management platform
What to look for when Dollar Tree (DLTR) reports Q3 2024 earnings
Shares of Dollar Tree, Inc. (NASDAQ: DLTR) rose over 5% on Monday. The stock has dropped 27% over the past three months. The discount store chain is scheduled to report
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training